Post-traumatic stress disorder (PTSD) is a serious mental health condition that can significantly impair daily functioning. For UK patients who have not responded adequately to established treatments, a medical cannabis prescription may be an option worth exploring with a specialist clinician.
PTSD develops in some individuals after experiencing or witnessing a traumatic event — such as military combat, sexual assault, serious accident, natural disaster, or prolonged abuse. The condition is characterised by intrusive re-experiencing of the trauma (flashbacks and nightmares), persistent avoidance of trauma-related reminders, negative alterations in mood and thinking, and heightened arousal and reactivity such as hypervigilance, irritability, and sleep disturbance.
PTSD affects people across all demographics in the UK — veterans, emergency service workers, survivors of violence, and civilians who have experienced significant trauma. It is associated with high rates of comorbid depression, anxiety, and substance misuse, and can severely disrupt relationships, employment, and quality of life.
Standard first-line treatments include trauma-focused cognitive behavioural therapy (TF-CBT), eye movement desensitisation and reprocessing (EMDR), and pharmacotherapy with SSRIs or SNRIs. While these approaches are effective for many patients, a proportion of individuals do not achieve adequate remission and continue to experience debilitating symptoms.
Research into cannabis-based medicines for PTSD has grown considerably over the past decade, drawing particularly on data from programmes in Canada, Israel, and certain US states. Clinical literature suggests that some patients with PTSD report reductions in nightmare frequency and severity, improved sleep quality, and reduced hyperarousal following the use of cannabis-based medicines.
The endocannabinoid system is thought to play a role in fear extinction and memory consolidation — processes that are disrupted in PTSD. Cannabis compounds, particularly THC and CBD, may interact with this system in ways that modulate the trauma response, though the precise mechanisms are still being investigated.
UK professional bodies have begun to acknowledge cannabis-based medicines as a consideration for patients who have not responded to established evidence-based therapies. Cannabis-based medicines for PTSD should be understood as a supplementary or last-resort option rather than a first-line treatment.
Consultations for PTSD tend to be more detailed than those for purely physical conditions. The specialist will review your full mental health history, the nature of the traumatic event(s), your symptom profile, duration of illness, and all treatments tried to date. They will assess comorbidities and discuss how cannabis-based medicines might interact with your current medication regimen.
If prescribing is considered appropriate, specialists typically start at a low dose and titrate gradually. Products often include CBD-dominant formulations alongside carefully dosed THC, with attention to managing THC-related anxiety risk. Many PTSD patients access cannabis-based medicines as part of a broader care plan that continues to include psychological therapy.
Veterans and former emergency service personnel with PTSD may find that some charities and veteran support organisations can provide information about funding or subsidised pathways to medical cannabis treatment.
The information on this page is provided for general educational purposes only and does not constitute medical advice. Eligibility for medical cannabis in the UK is determined by a licensed specialist on an individual clinical basis. Always consult a qualified healthcare professional about your own situation.